Trial
NCT04045028
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics (PK), Pharmacodynamics (PD), and Preliminary Activity of Tiragolumab in Participants With Relapsed or Refractory Multiple Myeloma or With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma
Phase ITERMINATEDOPERATIONALConfidence: HIGH
Sponsor
Genentech, Inc.
Collaborators
—
Condition
Multiple Myeloma
Intervention
Tiragolumab
Why stopped
Slow recruitment
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2023-04-07